Chimeric antigen receptor T cell immunotherapy for refractory and relapsed acute lymphoblastic leukemia: Challenge and Countermeasures / 中华检验医学杂志

Chimeric antigen receptor(CAR)-T cell immunotherapy for refractory and relapsed acute lymphoblastic leukemia (R/R ALL) is one of the breakthroughs in the field of hematological malignant disease treatment. However, several challenges remain, such as immune rejection of allogeneic CAR-T cells, leukemia relapse, as well as could we apply CAR-T cell immunotherapy to ALL patients with positive measurable residual disease and those of newly diagnosed cases. The safety and efficiency of CAR-T therapy will be further improved for patients with ALL only by establishing appropriate strategies to address these challenges.

Relationship between bone relapse in pediatric acute lymphoblastic leukemia and gene mutation / 国际儿科学杂志

Acute lymphoblastic leukemia is a major type of childhood cancer.It is an obstacle to cure for young patients with relapsed acute lymphoblastic leukemia.Recent investigations into the mechanism of relapse in pediatric acute lymphoblastic leukemia indicate the relationship between gene abnormalities and the relapse of pediatric acute lymphoblastic leukemia.An increasing number of gene abnormalities have been confirmed to be related with relapse of this disease, including deletion of IKZF1 and mutations of JAK, CREBBP,CEBPE and ARID5B.This paper reviews the details about the influence of the various gene mutations on the relapse of the pediatric acute lymphoblastic leukemia.